Apimeds Pharmaceuticals US
APUS
7 hedge funds and large institutions have $649K invested in Apimeds Pharmaceuticals US in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0.32% → 0.31% (-0%)
9% less capital invested
Capital invested by funds: $712K → $649K (-$62.9K)
13% less funds holding
Funds holding: 8 → 7 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$58K |
| 2 |
HTHT
Hemenway Trust Hemenway Trust
Salem,
New Hampshire
|
+$51.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.83K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.24K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$21 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$49.6K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$33.3K |
| 3 |
HF
HRT Financial
New York
|
-$24K |
| 4 |
JP Morgan Chase
New York
|
-$14 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HTHT
1
Hemenway Trust Hemenway Trust
Salem,
New Hampshire
| $449K | +$51.2K | +2,400 | +10% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $96.7K | – | – | – |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $57.2K | +$8.83K | +414 | +13% |
|
|
4
Jane Street
New York
| $44.6K | +$58K | +2,719 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $954 | +$1.24K | +58 | New |
|
|
6
Bank of America
Charlotte,
North Carolina
| $66 | +$21 | +1 | +33% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $16 | +$21 | +1 | New |
|
|
8
Renaissance Technologies
New York
| – | -$49.6K | -2,789 | Closed |
|
|
XT
9
XTX Topco
George Town,
Cayman Islands
| – | -$33.3K | -1,874 | Closed |
|
|
HF
10
HRT Financial
New York
| – | -$24K | -1,357 | Closed |
|
|
11
JP Morgan Chase
New York
| – | -$14 | -1 | Closed |
|
APUS Hedge Fund Activity: Q4 2025 in Review
7 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Apimeds Pharmaceuticals US (APUS) for Q4 2025, worth a combined $649K — down 8.8% from $712K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of APUS and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was Jane Street, opening a new position worth an estimated $58K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $49.6K sold.
- 7 institutional investors held Apimeds Pharmaceuticals US (APUS) as of Q4 2025, down from 8 in Q3 2025.
- Funds reported $649K of Apimeds Pharmaceuticals US stock for Q4 2025, down 8.8% quarter-over-quarter.
- 3 funds opened new Apimeds Pharmaceuticals US positions in Q4 2025 and 4 closed out, a net change of -1 holder.
- The largest Apimeds Pharmaceuticals US buyer in Q4 2025 was Jane Street, an estimated $58K added.
- The largest Apimeds Pharmaceuticals US seller in Q4 2025 was Renaissance Technologies, an estimated $49.6K sold.
Based on aggregated 13F filings for Q4 2025.